precisionmedicineonline23h
Maze Therapeutics Doses First Patient in Phase II APOL1 Inhibitor Kidney Disease Trial
Within the open-label basket trial, patients with two copies of one of two high-risk APOL1 gene variants will receive MZE829.
Kidneys from Black donors are more likely to be thrown away − a bioethicist explains why
As it is now, the transplant system treats kidneys from all Black donors as if they are at higher risk for failing, even ...
The Lancet15h
A new pathway for primary aldosteronism treatment
An oft-repeated message is that primary aldosteronism is not rare; it is quite common. An equally urgent message is that ...
The Lancet15h
Long-term outcomes and challenges of islet transplantation in type 1 diabetes
In patients with frequent severe hypoglycaemic events, allogeneic pancreatic islet transplantation results in better glycaemic control than insulin therapy alone, enhances quality of life, and reduces ...
Lupus Foundation of America19h
UPDATE: Gazyva® Shows Superiority Over Standard Therapy for People with Active Lupus Nephritis
The New England Journal of Medicine has published a detailed analysis of Genentech’s positive results from the Phase III REGENCY study of Gazyva® (Obinutuzumab) for people with active lupus nephritis ...